EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real‐World Clinical Study

Shun Kaneko iD, Yasuhiro Asahina, Miyako Murakawa iD, Shunsuke Ueyama, Hideki Watanabe, Chiaki Maeyashiki, Akiko Kusano-Kitazume, Ayako Sato, Kozue Uchidate, Taro Watabe, Takehito Asakawa, Sho Watanabe und 21 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71171 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Shun Kaneko und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant-in-Aid for Scientific Research, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aim The global aging population includes an increasing number of elderly patients with hepatocellular carcinoma (HCC). This study aimed to clarify the real‐world outcomes, prognostic factors, and appropriate administration indicators for immunotherapy in elderly HCC patients.

Methods

This retrospective multicenter study analyzed 286 patients with unresectable HCC who received first‐line immunotherapy (atezolizumab–bevacizumab or durvalumab‐tremelimumab) between November 2020 and January 2024. Patients were categorized into the late elderly (LE; ≥ 75 years, n = 117) and non‐late elderly (non‐LE; ≤ 74 years, n = 169) groups. Baseline characteristics, overall survival (OS), progression‐free survival (PFS), and prognostic factors were evaluated.

Results

The LE group had significantly poorer performance status, lower albumin–bilirubin (ALBI) scores, lower alpha‐fetoprotein (AFP) and alanine transaminase levels, higher creatinine levels, and were significantly less likely to receive post‐immune checkpoint inhibitor (ICI) treatment compared with the non‐LE group (56.2% vs. 38.4%, p = 0.0038). Median OS and PFS for the LE group were 25.6 and 10.5 months, respectively. The LE group demonstrated a comparable disease control rate (82.0%) and safety profile. The ALBI score was a significant prognostic factor for both groups. Post‐ICI treatment significantly improved OS only in the non‐LE group, even after propensity score matching for ALBI score and AFP levels.

Conclusions

Immunotherapy is effective and well‐tolerated in LE patients with unresectable HCC, particularly in those with preserved liver function (mALBI grade 1/2a). Post‐ICI treatment significantly benefits non‐LE patients, with limited impact on LE patients, highlighting the need for therapeutic strategies based on age and liver function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsImmunotherapyImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansAgedMaleFemaleRetrospective StudiesAged, 80 and overBevacizumabAntibodies, Monoclonal, HumanizedMiddle AgedPrognosisAge FactorsProgression-Free SurvivalAntibodies, Monoclonal

Stichwörter der Autor:innen

ALBI scoreatezolizumab plus bevacizumabdurvalumab‐tremelimumabhepatocellular carcinomapost‐ICI treatment

Substanzen

BevacizumabImmune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedatezolizumabdurvalumabtremelimumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Tsuchiura Kyodo General Hospital, Ibaraki, Japan.
  • Department of Gastroenterology and Hepatology, Yokosuka Kyosai Hospital, Kanagawa, Japan.
  • Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.

ORCID-Profile: Shun Kaneko, Miyako Murakawa, Fukiko Kawai-Kitahata

Förderung

  • Grant-in-Aid for Scientific Research
  • Japan Agency for Medical Research and Development

Zitieren

APA

Kaneko, S., Asahina, Y., Murakawa, M., Ueyama, S., Watanabe, H., Maeyashiki, C., Kusano-Kitazume, A., Sato, A., Uchidate, K., Watabe, T., Asakawa, T., Watanabe, S., Fujiki, J., Shibata, I., Oooka, S., Kurata, H., Tsuchiya, M., Fujii, T., Akahoshi, K., …, & Ochanomizu Liver Conference Study Group (2025). Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real‐World Clinical Study. Cancer Medicine. https://doi.org/10.1002/cam4.71171

Vancouver

Kaneko S, Asahina Y, Murakawa M, Ueyama S, Watanabe H, Maeyashiki C, et al. Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real‐World Clinical Study. Cancer Medicine. 2025. doi:10.1002/cam4.71171

BibTeX
@article{Kaneko2025,
  author = {Kaneko, Shun and Asahina, Yasuhiro and Murakawa, Miyako and Ueyama, Shunsuke and Watanabe, Hideki and Maeyashiki, Chiaki and Kusano-Kitazume, Akiko and Sato, Ayako and Uchidate, Kozue and Watabe, Taro and Asakawa, Takehito and Watanabe, Sho and Fujiki, Junko and Shibata, Isamu and Oooka, Shinya and Kurata, Hitoshi and Tsuchiya, Mao and Fujii, Takashi and Akahoshi, Keiichi and Ban, Daisuke and Inada, Kento and Nobusawa, Tsubasa and Mochida, Tomohiro and Watakabe, Keiya and Shimizu, Taro and Tsuchiya, Jun and Miyoshi, Masato and Kawai-Kitahata, Fukiko and Nitta, Sayuri and Nakagawa, Mina and Kakinuma, Sei and Okamoto, Ryuichi and Ochanomizu Liver Conference Study Group, Ochanomizu Liver Conference Study Group},
  title = {Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real‐World Clinical Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71171}
}
Kostenlos starten →